Dogan Koca1, Ilhan Oztop, Ugur Yilmaz. 1. Dokuz Eylül University, Medical Faculty, Department of Internal Diseases, Divison of Medical Oncology, İnciraltı, 35340, Izmir, Turkey.
Abstract
OBJECTIVES: This study is aimed to evaluate patients with non-metastatic rectal cancer who could not be operated due to any reason and were treated with chemoradiotherapy alone or chemotherapy following chemoradiotherapy. METHODS: Patients with locally advanced non-metastatic rectal cancer, who were treated and followed-up were evaluated. RESULTS: Totally 263 patients with stage II and III rectal cancer were evaluated. It was determined that 14 (5.2%) of the patients with locally advanced stages received chemoradiotherapy alone or chemotherapy following chemoradiotherapy, and they were followed-up instead of undergoing operation. The baseline assessments revealed that 8 (57.1%) patients had clinical stage II, and 6 (42.9%) patients had clinical stage III diseases. Recurrence was detected in 3 (21.4%) patients. 6 (42.9%) patients died, and death due to rectal cancer progression was detected in 2 (14.3%) patients. Median progression-free survival was 25 months (8 to 68 months), median overall survival was 35 months (12 to 68 months), overall survival rates in 1, 3 and 5 years were 92.9%, 69.8% and 52.4%, respectively. CONCLUSIONS: Chemoradiotherapy alone or subsequent chemotherapy after chemoradiotherapy may be suitable for patients with non-metastatic locally advanced rectal cancer who could not be operated due to any reason.
OBJECTIVES: This study is aimed to evaluate patients with non-metastatic rectal cancer who could not be operated due to any reason and were treated with chemoradiotherapy alone or chemotherapy following chemoradiotherapy. METHODS:Patients with locally advanced non-metastatic rectal cancer, who were treated and followed-up were evaluated. RESULTS: Totally 263 patients with stage II and III rectal cancer were evaluated. It was determined that 14 (5.2%) of the patients with locally advanced stages received chemoradiotherapy alone or chemotherapy following chemoradiotherapy, and they were followed-up instead of undergoing operation. The baseline assessments revealed that 8 (57.1%) patients had clinical stage II, and 6 (42.9%) patients had clinical stage III diseases. Recurrence was detected in 3 (21.4%) patients. 6 (42.9%) patients died, and death due to rectal cancer progression was detected in 2 (14.3%) patients. Median progression-free survival was 25 months (8 to 68 months), median overall survival was 35 months (12 to 68 months), overall survival rates in 1, 3 and 5 years were 92.9%, 69.8% and 52.4%, respectively. CONCLUSIONS: Chemoradiotherapy alone or subsequent chemotherapy after chemoradiotherapy may be suitable for patients with non-metastatic locally advanced rectal cancer who could not be operated due to any reason.
Authors: N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher Journal: J Natl Cancer Inst Date: 2000-03-01 Impact factor: 13.506
Authors: Chiara Carlomagno; Stefano Pepe; Francesco Paolo D'Armiento; Maria D'Armiento; Lucia Cannella; Alfonso De Stefano; Anna Crispo; Marcella Giordano; Sabino De Placido Journal: Oncology Date: 2010-08-26 Impact factor: 2.935
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: J E Krook; C G Moertel; L L Gunderson; H S Wieand; R T Collins; R W Beart; T P Kubista; M A Poon; W C Meyers; J A Mailliard Journal: N Engl J Med Date: 1991-03-14 Impact factor: 91.245